Branded Products Strategy. Helmut Kraft, CFO

Transcription

1 Branded Products Strategy Helmut Kraft, CFO

2 Changing the face of STADA Branded Products contribute 51% to adjusted operating profit 1) 46% 51% 51% 36% 37% 32% 26% 27% 28% 33% 36% 39% /2014 Share of Branded Products in sales 1) Share of Branded Products in adjusted operating profit 1) 1) of the two core segments Generics and Branded Products. Capital Markets Day September 16,

3 Buy-and-build: Successful acquisitions Year Acquisitions Purchase price Region Indication 2009 Eunova 12 million Germany Dietary supplement 2011 Cetraben 35 million United Kingdom Derma product range for the treatment of skin eczema and dry skin 2011/2012 Grünenthal Branded Products Portfolio 312 million Central Europe, Eastern Europe and Middle East Pain medication such as Tramal, Zaldiar, Transtec, Palexia 2012 Tranexam, Vuka Vuka, Vuka Drive, Ingavirin, Safocid 10 million Russia, Eastern Europe/CIS Various Indications 2012 Branded products portfolio 15 million Ukraine Womens health 2013 Thornton & Ross Ltd. 226 million United Kingdom Various OTC products 2013 Aqualor 131 million Russia, Eastern Europe/CIS Sprays and drops for the treatment of sinusitis 2014 Flexitol 13 million UK, Ireland Hand and foot care Capital Markets Day September 16,

4 Our platform

5 Branded Products Growth Sales (in million) % Adj. EBITDA (in million) % Regional development CIS/Eastern Europe million -5% (+2%) Asia & Pacific 12.3 million +40% (-9%) 38.3% 3.2% Germany 79.8 million +9% (+9%) 20.9% 1-6/ / / / % Central Europe million +46% (+6%) 1-6/2014 Key countries Germany with higher profitability CIS/Eastern Europe with sales growth in local currencies despite CIS crisis (+11.2%) Thornton & Ross highly dynamic ApoGo on the growth path Sales 1-6/2014 in EUR Russia Germany UK Italy Vietnam Ukraine Serbia Spain Capital Markets Day September 16,

6 Climbing the performance ladder 1) 6M/2010 6M/2014 OTC corporation Sales in m 1 Novartis 1,338 2 Bayer 1,160 3 Sanofi 1,074 4 Johnson & Johnson GlaxoSmithKline Teva Reckitt Benckiser Boehringer Ingelheim Bristol-Myers Squibb Roche Abbott Pierre Fabre STADA Menarini 302 Total Market 19,808 OTC corporation Sales in m 1 Novartis 1,541 2 Bayer 1,179 3 Sanofi 1,163 4 Johnson & Johnson Teva Reckitt Benckiser Boehringer Ingelheim GlaxoSmithKline STADA Abbott Roche Menarini Braun-Melsungen Bristol-Myers Squibb 309 Total Market 21,072 1) Source: IMS Health MIDAS EU28+RU+CH+NO+RS Panel: Retail + Hospital MAT/06/2014 Capital Markets Day September 16,

7 Market leading brands 1-6/2014 No. Branded Product Growth in % Sales in million Indication 1. Ladival (OTC) Sun Protection 2. ApoGo (RX) Parkinson 3. Grippostad (OTC) Cough and cold 4. Aqualor 1) (OTC) 13.5 Rhinitis 5. Snup (OTC) Rhinitis 6. Vitaprost (RX) Prostate hyperplasia 7. Hirudoid (OTC) Inflammation of the veins 8. Chondroxide (OTC) Muscular and joint pain 9. Tramal (RX) Chronic pain 10. Care 2) (OTC) 8.7 Umbrella brand All Branded Products ) Sales of Aqualor : initial consolidation as from March 1, ) Umbrella brand for various indications such as skin care, cold medicine, gastrointestinal disease, pain medication, among others. Capital Markets Day September 16,

8 Positive impact on Group sales and margins 2, ,000 1,500 1, Adjusted 1) EBITDA margin in % Sales in million / Expansion of self-pay portfolio Shift to high margin product/country mix Economies of scale effects (volume gains) 1) Adjusted for one-time special effects ( ) and non-operational effects from currency influences (2009/2010) Capital Markets Day September 16,

9 Operating excellence Operating profit margins in consumer health 1-6/ % 23% 20% 17% 17% 14% % 0 STADA 1) Reckitt 2) Merck CH 3) Perrigo 4) Bayer CH 5) GSK CH 6) Novartis CH 7) 1) Adj. operating profit H1/2014 2) Adj. op. profit H1/2014 (Health, Hygiene, Home & Portfolio) 3) EBIT H1/2014 4) Op. Income, FY 2014 (August 14) 5) EBIT H1/2014 6) Core op. profit H1/2014 7) Core op. income H1/2014 Source: Financial reports, CH = Consumer Health Care Capital Markets Day September 16,

10 Our approach

11 STADA today Positioning Organic and acquired growth Complex portfolio As yet predominantly local heroes Different customer groups Strengths Close to market and customer High personal responsibility Quick and flexible decision making Highly motivated and efficient Decentralised approach Risks Desynchronized marketing activities Low synergy potential Higher costs and organisational effort Capital Markets Day September 16,

12 STADA tomorrow Blend of decentralised & centralised approach Combination of consistent, centralized brand guidance with close to market, decentralized navigation Centralised branded products portfolio management Measures Introduce appropriate guidelines and structures Select and travel a limited number of strategic brands based on their growth potential ( countryby-country view ), e.g. Ladival, Snup Maintain leading local heroes Strengthen innovation potential, category management Selectively add expertise to regional set-up Acquisition of Thornton & Ross as a catalyst to optimize corporate structure and performance Capital Markets Day September 16,

13 Expertise across all channels STADA Wholesale Pharmacy/Hospital Pharmacy/Hospital Retail chains (UK) Customer/Patient Capital Markets Day September 16,

14 Building brand equity OTC-Market Large and growing markets: Higher life expectancy, aging population Greater health awareness promotes increasing out-ofpocket spending Cost pressure in health care forces personal responsibility = market of selfpaying patients Our approach Consistent brand guidance and close to market navigation Consistent portfolio development Realizing opportunities on organic side is first priority Best in class innovation and customer service Optimize operational leverage Disciplined and smart bolt-on acquisitions Where we want to go Create true beacon brands for aspirational consumers Trigger high level of dynamism to become a leader in brand management International footprint and mind-set Passing 1 bn revenue level in Branded Products Diversify Branded Products / generic mix from ~ 50% to ~ 2/3 Group operating profit contribution Capital Markets Day September 16,